20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kymera Therapeutics Inc (KYMR) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 273 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, KYMR reported $39M in revenue and ($311M) in net income.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.
Interactive charts & full statements → Open the KYMR valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $105M | $39M | $47M | $79M | $47M | $73M | $34M | $3M | $0M |
| Gross Profit | — | $39M | $47M | $79M | $47M | $73M | $34M | $2M | $0M |
| Gross Margin % | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 71.9% | — |
| Operating Income (EBIT) | ($351M) | ($349M) | ($262M) | ($166M) | ($161M) | ($101M) | ($46M) | ($42M) | ($21M) |
| Operating Margin % | -334.3% | -891.3% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% | — |
| Net Income | ($299M) | ($311M) | ($224M) | ($147M) | ($155M) | ($100M) | ($46M) | ($41M) | ($21M) |
| Net Margin % | -284.8% | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1407.4% | — |
| EBITDA | — | ($303M) | ($216M) | ($143M) | ($152M) | ($98M) | ($44M) | ($40M) | ($21M) |
| Earnings Per Share (EPS) | $-3.30 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.02 | $-0.93 | $-0.48 |
| Shares Outstanding (M) | — | 84M | 75M | 58M | 54M | 48M | 45M | 45M | 45M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $65M | $34M | $3M | $3M | $11M | $22M | $7M | $4M | $26M |
| Gross Profit | — | $34M | $79M | ($71M) | $9M | $22M | $7M | $4M | $26M |
| Gross Margin % | — | 100.0% | 2763.6% | -2580.7% | 81.8% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($76M) | ($84M) | ($98M) | ($93M) | ($85M) | ($74M) | ($81M) | ($72M) | ($51M) |
| Operating Margin % | -116.9% | -244.9% | -3422.9% | -3347.4% | -736.8% | -336.8% | -1092.2% | -1927.9% | -198.5% |
| Net Income | ($61M) | ($69M) | ($87M) | ($82M) | ($77M) | ($66M) | ($71M) | ($62M) | ($42M) |
| Net Margin % | -93.8% | -201.5% | -3043.0% | -2973.0% | -667.6% | -296.8% | -956.9% | -1670.3% | -164.0% |
| EBITDA | — | ($67M) | ($85M) | ($79M) | ($74M) | ($63M) | ($69M) | ($60M) | ($40M) |
| Earnings Per Share (EPS) | $-0.62 | $-0.71 | $-1.03 | $-0.94 | $-0.95 | $-0.82 | $-0.88 | $-0.82 | $-0.58 |
| Shares Outstanding (M) | — | 98M | 84M | 87M | 80M | 80M | 80M | 76M | 73M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($237M) | ($233M) | ($195M) | ($103M) | ($153M) | ($129M) | $88M | $18M | ($18M) |
| Capital Expenditures (CapEx) | $0M | $1M | $13M | $34M | $3M | $2M | $9M | $1M | $1M |
| Free Cash Flow (FCF) | ($237M) | ($234M) | ($207M) | ($137M) | ($156M) | ($131M) | $79M | $17M | ($19M) |
| FCF Margin % | -225.7% | -597.8% | -440.5% | -174.7% | -333.0% | -179.2% | 232.2% | 592.1% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($54M) | ($89M) | ($67M) | ($27M) | ($60M) | ($79M) | ($62M) | ($50M) | ($43M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $1M | $0M | $5M |
| Free Cash Flow (FCF) | ($54M) | ($89M) | ($67M) | ($27M) | ($61M) | ($80M) | ($63M) | ($50M) | ($48M) |
| FCF Margin % | -83.1% | -259.8% | -2337.5% | -987.4% | -527.9% | -360.3% | -848.3% | -1346.7% | -185.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B | $1.7B | $978M | $576M | $603M | $606M | $487M | $117M | $44M |
| Cash & Cash Equivalents | $124M | $357M | $120M | $110M | $68M | $48M | $31M | $76M | $41M |
| Total Liabilities | $136M | $163M | $142M | $181M | $113M | $146M | $203M | $191M | $79M |
| Total Debt (Short + Long-Term) | — | $14M | $13M | $6M | $4M | $4M | $3M | $3M | $0M |
| Total Shareholders' Equity | $1.5B | $1.6B | $836M | $395M | $490M | $460M | $284M | ($74M) | ($34M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KYMR viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms